Modra Pharmaceuticals is contributing to modern cancer treatment options by improving the delivery and bioavailability of chemotherapy, the backbone of oncology regimens today.
‘Modra’ is a contraction of Modulated Oral Drug Absorption and was founded in June 2010 as a spin-off of the Netherland's Cancer Institute (Nederlands Kanker Instituut Antoni van Leeuwenhoek) and MC Slotervaart Hospital in Amsterdam. Our focus is on using our proprietary technology to address an unmet need for improving cancer patient’s quality of life while reducing the side effects and improving the therapeutic index vs traditional IV chemotherapy.
Through our oral formulation technology, we can bypass limitations of IV-delivered drugs, enabling a better product for patients. Our pipeline includes two of the most broadly used chemotherapies, docetaxel and paclitaxel, which we will advance rapidly through clinical evaluation. Our vision is to work together with cancer leaders and innovators to be an integral part of the rapidly evolving landscape of combination therapy and expedite the development of next-generation cancer regimens.